Clinical trials: Recurrence Tumor
Colorectal Carcinoma
Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma
The purpose of this study is to exploratorily examine efficacy and safety in the participants with chemotherapy-naïve unresectable, advanced/recurrent colorectal carcinoma of Kirsten rat sarcoma-2 virus (KRAS) wild-type who have…
- Trial name
- SAPPHIRE (NCT02337946)
- Testing
- oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
- Where
- 49 sites in Japan
- Volunteers
- 164 people
- Sponsor
- Takeda
Earlobe Keloids
A Post Market Study Evaluating the Safety, Device Perfomance and Possible Emergent Risks of Celotres in Preventing Recurrence in Keloid Lesions Treated Adjunctive to Surgical Excision
The objective of the study is to actively gather additional information on safety, device performance and possible emergent risks following the use of Celotres in a post-market setting when used to reduce the recurrence rate…
- Trial name
- EURO KLEAR (NCT01706861)
- Testing
- Celotres
- Where
- 6 sites in Poland, The Bahamas and 1 more
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Halscion, Inc.
Nasopharyngeal Cancer Recurrent
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.
- Trial name
- TRANSPARENT (NCT06457503)
- Testing
- Toripalimab, Cisplatin, Gemcitabine
- Where
- 13 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Coherus Oncology, Inc.
Solid Tumors
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab
This study will be conducted in 5 parts (Parts A, B, C, D and E). Monotherapy Treatment: Subjects ≥18 years with advanced solid tumors will be enrolled in the study. Monotherapy dose escalation will be performed in Part A.
- Trial name
- NCT02628574
- Testing
- TRX518 monotherapy, TRX518 with gemcitabine, TRX518 with pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- Leap Therapeutics, Inc.
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
- Trial name
- RAMP 201 (NCT04625270)
- Testing
- avutometinib (VS-6766), avutometinib (VS-6766) and defactinib
- Where
- 47 sites in United States, Belgium and 5 more
- Volunteers
- 225 people
- Sponsor
- Verastem, Inc.
HCC
CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
A Single-arm, Open-label, Multicenter, Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of CT011 Autologous CAR-T Cells in Patients with Hepatocellular Carcinoma at Risk of Recurrence after Surgical Resection.
- Trial name
- NCT06560827
- Testing
- CT011 CAR-GPC3 T Cells Injection
- Where
- 15 sites in China
- Volunteers
- 30 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic pancreatic cancer and metastatic breast cancer.
- Conditions
- Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation, Pancreatic Acinar Cell Carcinoma
- Trial name
- SHARON (NCT04150042)
- Testing
- Melphalan, BCNU, Vitamin B12B
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- General Oncology, Inc.
Multiple Myeloma
A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the tolerability and safety of Daratumumab in Japanese participants with relapsed (the return of a medical problem) or refractory (not responding to treatment) multiple myeloma (cancer of…
- Trial name
- NCT02116569
- Testing
- Daratumumab
- Where
- 2 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Janssen Pharmaceutical K.K.
Lymphoma
Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with relapsed and refractory lymphoma.
- Trial name
- NCT00359086
- Testing
- MGCD0103
- Where
- 5 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- Mirati Therapeutics Inc.
Multiple Myeloma and Plasma Cell Neoplasm
Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00017069
- Testing
- arsenic trioxide, dexamethasone
- Where
- 10 sites in United States
- Sponsor
- CTI BioPharma
NHL, Relapsed, Adult, B-cell Lymphoma
Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies
This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).
- Conditions
- NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma
- Trial name
- ANCHOR2 (NCT05487651)
- Testing
- KUR-502
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Athenex, Inc.
Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
This study is being done to find the best dose of an investigational drug called NBM-BMX for people with metastatic uveal melanoma, a type of eye cancer that has spread to other parts of the body.
- Conditions
- Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic, Uveal Melanoma, Recurrent, Eye Cancer, Intraocular Melanoma
- Trial name
- NBM-BMX-UM (NCT07136181)
- Testing
- NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Novelwise Pharmaceutical Corporation
Stomach Neoplasms
A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer
The purpose of this study is to assess the effectiveness, safety, and actual treatment status of first-line nivolumab plus chemotherapy in participants with untreated advanced / recurrent gastric cancer in a Japanese real-world…
- Trial name
- G-KNIGHT (NCT05334719)
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Bristol-Myers Squibb
Recurrence of Clostridium Difficile Infection
REBYOTA™ Prospective Registry
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting.
- Trial name
- ROAR (NCT05835219)
- Testing
- REBYOTA™
- Where
- 42 sites in United States
- Volunteers
- 145 people
- Sponsor
- Ferring Pharmaceuticals
Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 and the combination of MRG003 and HX008 in patients with recurrent or metastatic squamous cell carcinoma of head and…
- Trial name
- NCT04868162
- Testing
- MRG003, MRG003+HX008
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Biochemical Recurrence of Malignant Neoplasm of Prostate
64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-bisPSMA and determine the ability of 64Cu-SAR-bisPSMA Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of…
- Trial name
- COBRA (NCT05249127)
- Testing
- 64Cu-SAR-bisPSMA
- Where
- 5 sites in United States
- Volunteers
- 52 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Relapsed or Refractory Mantle Cell Lymphoma
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about…
- Trial name
- NCT01833039
- Testing
- Ibrutinib
- Where
- 51 sites in United States, Brazil and 1 more
- Sponsor
- Janssen Biotech, Inc.
Multiple Myeloma
Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
For each subject the study will consist of two phases: a treatment phase and a follow-up phase. Screening procedures will take place within 28 days of baseline.
- Trial name
- NCT00065351
- Testing
- CC-5013
- Where
- 26 sites in United States
- Volunteers
- 222 people
- Sponsor
- Celgene
Brain and Central Nervous System Tumors
Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of leflunomide in treating patients who have anaplastic…
- Trial name
- NCT00003775
- Testing
- leflunomide
- Where
- 26 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Pfizer
B-cell Non-Hodgkin's Lymphoma
Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)
An open-label, single-arm, phase II clinical study of anti-PD-1 antibody GB226 in treatment of recurrent or refractory B-cell non-Hodgkin's lymphoma (B-NHL)
- Trial name
- NCT03639181
- Testing
- GB226
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Genor Biopharma Co., Ltd.